NCT01831804View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Single and Repeated Doses of Topical GSK1278863

PHASE1CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

June 17, 2013

Primary Completion Date

February 10, 2017

Study Completion Date

February 10, 2017

Conditions
Wound Healing
Interventions
DRUG

GSK1278863

White to off-white smooth ointment with unit dose strength of 0.05%w/w, 0.1%w/w, 0.5%w/w, 1.0%w/w for topical application as single or repeat doses.

DRUG

Placebo

White to off-white smooth ointment for topical application as single or repeat doses.

Trial Locations (7)

20007

GSK Investigational Site, Washington D.C.

33176

GSK Investigational Site, Miami

33782

GSK Investigational Site, Pinellas Park

75390

GSK Investigational Site, Dallas

89106

GSK Investigational Site, Las Vegas

94546

GSK Investigational Site, Castro Valley

02903

GSK Investigational Site, Providence

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01831804 - Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Single and Repeated Doses of Topical GSK1278863 | Biotech Hunter | Biotech Hunter